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Abstract
: Type 2 diabetes is caused by defects in both insulin signaling and insulin secretion. Though the role
of the ubiquitin proteasome system (UPS) in the pathogenesis of type 2 diabetes remains largely
unexplored, the few examples present in the literature are interesting and suggest targets for drug
development. Studies indicate that insulin resistance can be induced by stimulating the degradation
of important molecules in the insulin signaling pathway, in particular the insulin receptor substrate
proteins IRS1, IRS2 and the kinase AKT1 (Akt). In addition, a defect in insulin secretion could occur
due to UPS-mediated degradation of IRS2 in the β-cells of the pancreas. The UPS also appears to
be involved in regulating lipid synthesis in adipocytes and lipid production by the liver and could
influence the development of obesity. Other possible mechanisms for inducing defects in insulin
signaling and secretion remain to be explored, including the role of ubiquitylation in insulin receptor
internalization and trafficking.
Publication history: Republished from Current BioData's Targeted Proteins database (TPdb;
http://www.targetedproteinsdb.com).
Protein pathway involvement in disease
Introduction
The global incidence of diabetes mellitus (commonly
referred to as diabetes) is increasing at such a rate as to be
characterized as an epidemic. This is primarily due to
changes in lifestyle that have led to obesity, a major risk
factor for diabetes. In both developed and many develop-
ing societies, people have become more sedentary,
thereby expending fewer calories. They have also adopted
diets with greater calories, resulting in a net positive
caloric balance stored in the body as fat (reviewed in
[1,2]).
Diabetes is a metabolic disorder, the primary manifesta-
tion of which is elevated circulating blood glucose levels.
Levels of blood glucose are normally maintained within a
tight range of around 3.6–6.0 mM. Elevation of blood glu-
cose, such as occurs after a meal, triggers the release of
insulin from the β-cells of the islets of Langerhans in the
pancreas. The circulating insulin has two major effects.
One is to stimulate glucose uptake into cells by promoting
the recruitment of a specific isoform of glucose trans-
porter, GTR4 (GLUT4), from intracellular vesicles to the
plasma membrane [3]. GTR4 is primarily expressed in
skeletal muscle and adipose tissue [4]. Skeletal muscle
accounts for the majority of insulin-stimulated glucose
disposal after a meal, due to its larger overall mass. The
other major effect of insulin is to suppress glucose produc-
tion by the liver. The production of glucose by the liver is
crucial for maintaining blood glucose levels in the fasted
state and occurs by the breakdown of glycogen stores. Glu-
cose can also be produced by the liver via de novo synthesis
from amino acids and glycerol generated by the break-
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down of protein stores in skeletal muscle and fat stores in
adipose tissue, respectively (reviewed in [5]).
Although diabetes is best recognized as a disorder of glu-
cose homeostasis, numerous other metabolic abnormali-
ties are concomitant. Insulin is an anabolic hormone and
thus stimulates protein synthesis and lipogenesis and
inhibits protein degradation and lipolysis in target tissues.
Therefore, diabetes is characterized not only by elevated
blood glucose, but also by elevated levels of circulating
amino acids and free fatty acids (reviewed in [6-8]).
Classification of diabetes
Most cases of diabetes fall into one of two categories,
which are very distinct in their etiologies and pathogene-
sis [9]. Type 1 diabetes, which accounts for around 10% of
cases in most populations, is due to an autoimmune-
mediated destruction of the insulin-producing β-cells in
the pancreatic islets of Langerhans. When approximately
80–90% of β-cells are destroyed, diabetes becomes clini-
cally evident and patients require insulin replacement
therapy. Although typically occurring in youth (hence for-
merly called juvenile onset diabetes), type 1 diabetes can
also occur in adults.
Type 2 diabetes accounts for the vast majority of the
remaining cases of diabetes. This form of diabetes gener-
ally arises from the concurrent presence of two defects,
insulin resistance, which is due to a defect in insulin sign-
aling in target tissues, and a relative defect in pancreatic
insulin secretion. The requirement for a defect in insulin
secretion is demonstrated by obese insulin-resistant sub-
jects. These patients do not develop diabetes because they
are capable of secreting extremely high levels of insulin,
probably by increasing their β-cell mass. Since obesity
commonly results in insulin resistance, the worldwide
epidemic of obesity has produced a concomitant epi-
demic of type 2 diabetes. Fat is now known to secrete
humoral factors and some of these (e.g. leptin, adiponec-
tin and resistin) can modulate insulin sensitivity; thus, the
altered production of these adipokines in obesity could be
involved in predisposition to diabetes (reviewed in [10]).
Other, rare forms of diabetes exist. For example, muta-
tions in the insulin receptor can lead to severe insulin
resistance and clinical defects such as leprechaunism [11].
Mutations in mitochondrial DNA have also been associ-
ated with diabetes [12]. Moreover, certain drugs can
induce hyperglycemia or exacerbate pre-existing diabetes,
as well as unmask latent forms of this disease.
Mechanisms of insulin signaling
Circulating insulin exerts its effects by binding to insulin
receptors on target tissues, leading to the activation of
multiple signaling pathways (Figure 1) (reviewed in [13]).
The insulin receptor is a membrane receptor tyrosine
kinase and binding of insulin to this receptor induces a
conformational change, which activates the tyrosine
kinase activity on the cytoplasmic surface of the cell [14].
This results in both autophosphorylation of the receptor
and phosphorylation of other protein molecules. The
immediate substrates of the insulin receptor kinase are
members of the insulin receptor substrate (IRS) family
(reviewed in [15]). These IRS family members vary in their
relative importance in different cells and tissues and there-
fore can mediate specific actions of insulin. Phosphoryla-
tion of IRS proteins on tyrosine residues results in the
recruitment of signaling molecules to these proteins. This
recruitment is typically mediated by phosphotyrosine
binding motifs such as SH2 (Src homology 2) domains
and a key such signaling molecule is PI3-kinase. Recruit-
ment of PI3-kinase to IRS1 (IRS-1) results in the phospho-
rylation of membrane phosphoinositides [16], which
leads to membrane recruitment and activation of a down-
stream signaling kinase, AKT1 (Akt). Akt kinase, in turn,
phosphorylates other proteins, the identities of which are
largely unknown. However, several downstream targets of
AKT1 activation have been identified including FRAP
(mTOR) [17] and GSK [18], which lead to stimulation of
protein [19] and glycogen synthesis, respectively. Ulti-
mately, these changes result in the metabolic effects of
insulin as described above.
In cell culture, and importantly during fetal development,
insulin is a growth factor. The stimulation of cell prolifer-
ation by insulin is mediated through the activation of the
Ras-Raf-MAP kinase pathway [20-23]. Activation of this
pathway occurs due to the ability of insulin-stimulated
IRS1 to bind the GRB2 (Grb2) protein in proliferating
cells. This, in turn, recruits and activates the guanine
nucleotide exchange factor SOS (Sos), leading to the acti-
vation of the Ras-Raf-MAP kinase signaling pathway [20-
23].
Mechanisms of insulin secretion
Insulin secretion is tightly controlled by levels of circulat-
ing glucose and to a lesser extent, amino acids (Figure 2)
(reviewed in [24,25]). The ability of pancreatic β-cells to
act as a glucose sensor is mainly due to the expression of
specific isoforms of the glucose transporter and glucoki-
nase in these cells. β-cells express the GTR2 (GLUT2) iso-
form of glucose transporter, which has a Km for glucose
transport of 15–20 mM. Thus, glucose flux into these cells
is dependent on circulating concentrations of glucose. In
addition, the β-cell glucokinase has a Km of around 8
mM, which also allows generation of glucose-6-phos-
phate to be dependent on ambient glucose levels. There-
fore, high levels of glucose generate more glucose-6-
phosphate, which, through glycolysis and oxidative phos-
phorylation, leads to the production of ATP from ADP.BMC Biochemistry 2008, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2091/9/S1/S6
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General scheme of insulin signaling Figure 1
General scheme of insulin signaling. Insulin binding to its receptor activates the receptor tyrosine kinase activity. This 
leads to autophosphorylation of the receptor and recruitment and phosphorylation of insulin receptor substrate (IRS) proteins. 
Subsequently, other signaling molecules such as PI3-kinase (PI3K) and GRB2 are recruited, which leads to the activation of the 
Akt signaling pathway (which mediates many metabolic effects) and the MAP kinase pathway (which mediates cell proliferation), 
respectively. Insulin binding also leads to receptor internalization into endosomes. From endosomes, receptors can recycle 
back to the plasma membrane or traffic via multivesicular bodies to the lysosome for degradation. Phosphorylated IRS and the 
IRS-PI3K complex are signaling molecules that can be inactivated by degradation through the ubiquitin proteasome system. 
Receptor internalization and trafficking between the endosome and lysosome has been shown to be dependent on ubiquityla-
tion for other receptor tyrosine kinases, but the requirement for UBIQ (ubiquitin) in the case of the insulin receptor remains 
speculative. In some adipocyte cell lines, the ubiquitin protein ligase CBLB (Cbl-b) has been implicated in mediating transloca-
tion of the GTR4 (GLUT4) glucose transporter to the plasma membrane via a RHOQ (Tc10)-dependent pathway.BMC Biochemistry 2008, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2091/9/S1/S6
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General scheme of insulin secretion Figure 2
General scheme of insulin secretion. In the β-cells of the pancreas, elevated blood glucose leads to increased levels of 
intracellular glucose-6-phosphate.  Metabolism of the glucose-6-phosphate through glycolysis and mitochondrial metabolism, 
leads to increased levels of ATP and to lower levels of ADP. This sequentially results in inhibition of an ATP-sensitive K+ chan-
nel, depolarization of the plasma membrane, activation of a voltage-dependent Ca2+ channel, influx of Ca2+ and exocytosis of 
insulin. Mitochondrial metabolism participates in this process, not only by generating ATP, but also by modulating levels of 
other metabolites (e.g. GTP, cAMP, NADPH, glutamate, malonyl CoA), which might also contribute to glucose-stimulated insu-
lin secretion. The ATP-sensitive K+ channel and voltage-dependent Ca2+ channel are sites that could be modulated by the ubiq-
uitin proteasome system (UPS). In addition, β-cell survival can be impaired by UPS-mediated degradation of IRS2 in these cells 
(see text for details).BMC Biochemistry 2008, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2091/9/S1/S6
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This increased intracellular ratio of ATP to ADP results in
the inhibition of an ATP-sensitive K+  channel in the
plasma membrane. Decreased efflux of K+ leads to depo-
larization of the plasma membrane, which activates a
voltage-dependent Ca2+ channel. Ca2+ results in exocytosis
of insulin-containing secretory granules and the release of
insulin into the circulation. The mitochondrial metabo-
lism also generates several other metabolites that appear
to be able to stimulate insulin secretion beyond the effects
of the adenine nucleotides. Chronic hyperglycemia also
activates transcription of the insulin gene, resulting in de
novo synthesis of insulin.
Ubiquitylation and insulin resistance
The molecular mechanisms that result in cells becoming
resistant to insulin are only beginning to be defined [26].
In cell culture, resistance can occur due to downregulation
of insulin receptors. In patients with diabetes, a small
number of studies indicate that receptor numbers are
decreased in isolated strips of abdominal skeletal muscle
[27], but normal in hepatocytes isolated from liver biop-
sies [28]. More consistent are observations of decreased
receptor kinase activity in these samples, measured as the
degree of insulin-stimulated tyrosine phosphorylation of
the receptor and IRS1 [27,28]. Most of the insulin resist-
ance appears to be due to resistance at signaling molecules
downstream of the receptor. For example, in insulin resist-
ant states, IRS1 can become phosphorylated on serine res-
idues [29], reviewed in [30]. This serine phosphorylation
is associated with decreased insulin-stimulated tyrosine
phosphorylation of IRS1 resulting in the decreased ability
of this protein to mediate signaling. Interestingly, IRS
activity can also be lowered by degradation. In various cell
lines (for example CHO [31], MEF and NIH3T3 [32]),
both IRS1 and IRS2 (IRS-2) can be ubiquitylated and
degraded by the proteasome. This ubiquitylation appears
to be mediated by the proteins SOCS1 and SOCS3 [33],
which function as substrate recognition factors in the cul-
lin-RING ligases subset of ubiquitin protein ligases. Over-
expression of these proteins stimulates degradation of
IRS1 and IRS2 in cultured cells and in mouse liver [33].
The SOCS1 and SOCS3 proteins interact with the von
Hippel Landau (VHL) subfamily of cullin-RING ligases
and are induced by cytokines [34]. Such induction by
inflammatory factors is particularly interesting in light of
numerous recent observations suggesting that diabetes
and obesity are pro-inflammatory states and that inflam-
mation plays an important role in mediating insulin
resistance (reviewed in [35]).
Other studies also support a role for modulation of IRS
levels in mediating insulin resistance. For example, nitric
oxide (NO) has been implicated in mediating insulin
resistance, as iNOS knockout mice are more sensitive to
insulin and more resistant to diet-induced obesity than
wild-type mice [36]. A possible mechanism for these
effects is demonstrated by the induction of IRS1 degrada-
tion by iNOS and NO in cultured muscle cells [37]. In
addition, other cell culture models of insulin resistance,
such as osmotic stress or chronic exposure to insulin or
IGF1 (IGF-1), have been shown to promote degradation
of IRS2 in NIH3T3 cells [32]. IRS1 degradation also occurs
upon chronic insulin exposure of CHO cells that overex-
press the insulin receptor or IRS1 [31]. The exact mecha-
nisms and proteolytic system(s) responsible for the
degradation of IRS proteins in these latter situations
remain unknown. Nonetheless, it is clear that degradation
of IRS proteins can be a contributing factor in the devel-
opment of insulin resistance.
In addition, recent data suggest that resistance could also
occur more distally at the level of AKT1 due to loss of
activity of this signaling molecule. For example, stimula-
tion of NIH3T3 adipocytes by the cytokine TNFA (TNFα)
leads to the ubiquitylation and loss of AKT1. Interestingly,
this ubiquitylation of AKT1 appears to be dependent on
the activation of caspase 6, as ubiquitylation is blocked by
an inhibitor of this caspase [38]. Finally, as distal parts of
the signaling pathway become better defined, new roles
for ubiquitylation become identified. Insulin usually sup-
presses hepatic glucose production, and a key feature of
the insulin resistance in type 2 diabetes is increased glu-
cose output from the liver via gluconeogenesis. Insulin
exerts this effect by suppressing transcriptional activation
of genes encoding enzymes in the gluconeogenic path-
way. Recent findings indicate that insulin stimulates the
phosphorylation of one of these transcriptional activa-
tors, TORC2, and this phosphorylation leads to its ubiq-
uitylation and targeting for degradation by the COP1
ubiquitin protein ligase [39].
Another possible mechanism for modulating insulin sig-
naling is through the regulation of insulin receptor traf-
ficking. Like other membrane receptors, ligand binding
results in internalization of the receptor, which can either
be recycled to the plasma membrane or targeted to the lys-
osome for degradation. During this trafficking through
the cell in endosomes, the receptor remains active [40]
and so increased or more rapid trafficking could result in
attenuated signaling. In cell lines, such as HeLa and
HEK293, many receptor tyrosine kinases are known to be
ubiquitylated upon ligand stimulation and such ubiquit-
ylation is clearly involved in downregulation of the recep-
tor by stimulating the trafficking of the receptor from the
plasma membrane to the lysosome (reviewed in [41]).
Indeed, interfering with the downregulation of the recep-
tor (as occurs in cells with mutant forms of the receptor)
or the ubiquitin protein ligase (thus preventing their
interaction), results in increased levels of the receptor. In
the case of EGF [42,43] or HGF [44], this can lead to onco-BMC Biochemistry 2008, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2091/9/S1/S6
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genic transformation of the cells. Although multiple
receptors such as the EGF, PDGF and HGF receptors are
known to be ubiquitylated, whether ubiquitylation of
insulin or IGF1 receptors occurs under similar cell culture
conditions remains controversial, with conflicting obser-
vations for these very similar receptors [45,46]. However,
this does not preclude a role for ubiquitylation in down-
regulation of the insulin receptor, since other non-recep-
tor proteins are also ubiquitylated as part of the trafficking
process. For example, CBLB (Cbl-b) is a ubiquitin protein
ligase that ubiquitylates several receptors upon ligand
stimulation and loss of this protein's ability to do so
increases signaling [42,44,47] (reviewed in [48]). Interest-
ingly, characterization of mice deficient in the CBLB iso-
form reveals that these mice are protected from diet-
induced obesity and insulin resistance [49]. Thus, this loss
of CBLB activity could be stabilizing the insulin receptor
and/or increasing its signaling; however, this is yet to be
clearly demonstrated.
Ubiquitylation and insulin secretion
In contrast to the role of ubiquitylation in insulin action,
the role of the UPS in insulin secretion is less well defined.
Inhibitors of the proteasome can acutely enhance glucose-
stimulated insulin release from rat islets in culture [50],
but appear to have the opposite effect in a mouse β-cell
line [51]. Accumulation of ubiquitylated proteins, with
evidence of associated inhibition of proteasome activity,
has been described in cultured islets and β-cells [52] and
observed in the pancreas of the Zucker diabetic rats [53],
but whether this is a cause or a consequence of β-cell dam-
age remains unclear. Few specific substrates have been
identified. Levels of the ATP-sensitive K+ channel [54] and
the voltage-dependent Ca2+ channel [51] could be regu-
lated by the UPS. One intriguing substrate is IRS2, which
is required for β-cell survival and is degraded in the INS1
(INS-1) β-cell line upon chronic exposure to hyperglyc-
emia or IGF1. The hyperglycemia stimulates the phospho-
rylation of IRS2 on serine and threonine and this
phosphorylation appears to target the protein for degrada-
tion by the proteasome, as proteasome inhibitors block
this degradation [55]. Whether SOCS1 or SOCS3 are
involved in the ubiquitylation of IRS2 in these cells
remains unknown. Thus, chronic hyperglycemia could
employ this mechanism to decrease IRS2 and induce β-
cell apoptosis. Recently, the TNAP3 (A20) protein has
been shown to be induced in islets undergoing apoptosis
and to protect these cells from death [56]. TNAP3 is a dual
function protein containing both deubiquitylating and
ubiquitin ligase activities, although the exact mechanism
of the action of this protein in this situation remains
unclear.
Ubiquitylation and biological actions of insulin
In previous sections within Protein pathway involvement in
disease, the roles of ubiquitylation in modulating factors
that could be involved in causing diabetes were discussed.
Ubiquitylation also plays various roles in mediating the
actions of insulin. As described earlier, insulin has func-
tions other than stimulation of glucose uptake and sup-
pression of gluconeogenesis. Insulin stimulates
lipogenesis in fat, as well as the liver, by activating acetyl-
coA carboxylase, the rate-limiting enzyme in fatty acid
synthesis [57]. Upon fasting, lipogenesis is inhibited and
acetyl-coA carboxylase is inactivated as a result of low
insulin levels, as well as the effects of catecholamines and
glucagon. However, acetyl-coA carboxylase has also been
shown to be inactivated by degradation in adipose tissue.
Upon fasting, levels of the pseudokinase protein TRIB3
(Tribbles3) increase in murine fat and the protein associ-
ates with the ubiquitin protein ligase COP1, thus stimu-
lating the ubiquitylation and degradation of acetyl-coA
carboxylase [58]. Mice overexpressing TRIB3 in adipose
tissue are protected from diet-induced obesity.
Fat is normally transported in the blood in esterified form
as triglycerides and packaged with protein into lipopro-
tein particles. Synthesis of these apoprotein constituents
of the particle appears to be important in determining the
levels of lipoprotein particles and fat circulating in the
blood. Apoprotein B48 (apoB48) is the major apoprotein
in the VLDL and LDL particles, which are the major circu-
lating forms of lipid in the blood. Like most secreted pro-
teins, apoB48 enters the lumen of the ER following
synthesis. However, in human liver carcinoma HepG2
cells, a significant fraction of synthesized apoB48 is
exported from the ER lumen to be degraded by the ER-
associated degradation pathway [59]. This pathway
involves ubiquitylation of the exported proteins and deg-
radation by the proteasome. Interestingly, exposure of the
cells to proteasome inhibitors can inhibit degradation of
apoB48, resulting in increased secretion of the lipoprotein
containing it. Dietary omega-3 fatty acids are known to
lower levels of VLDL and, in intestinal explants from ger-
bils, this appears to be due to the ability of these fatty
acids to stimulate degradation of apoB48 [60].
Insulin is well recognized to be anabolic in skeletal mus-
cle, by stimulating protein synthesis and inhibiting pro-
tein degradation. Protein degradation in skeletal muscle is
dependent on the UPS. The cellular regulatory mecha-
nisms have actually been best described for IGF1, but
these mechanisms are also likely to apply to insulin, as the
signaling pathways of these proteins are very similar. IGF1
activates AKT1, which leads to the activation of FRAP
(mTor), the translation initiation factor IF4B (eIF4B) and
KS6B1 (p70S6) kinase, resulting in the stimulation of pro-
tein synthesis [17]. Simultaneously, AKT1 activation leadsBMC Biochemistry 2008, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2091/9/S1/S6
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to phosphorylation of members of the FOXO transcrip-
tion factors, which results in their exclusion from the
nucleus [61]. Nuclearly localized FOXO transcription fac-
tors normally activate the transcription of two important
ubiquitin protein ligases, TRI63 (MuRF1) and FBX32
(atrogin-1, MaFBx). In skeletal muscle, the increased
expression of these ligases is tightly associated with pro-
tein catabolism and inactivation of the genes coding for
these proteins in the mouse leads to blunted muscle atro-
phy [62]. Thus, growth factor-stimulated cytosolic reten-
tion of FOXO factors turns off protein degradation.
Increased expression of components of the ubiquitin pro-
teasome pathway has been observed in the muscles of
patients in catabolic states [63-66] but not in all situa-
tions. This is probably due to the activation of protein
expression when the wasting process is initiated and
might not be present in very early [67] or late stages of dis-
ease. Some of the suppressive effects of insulin might be
related to possible interactions between IDE, an enzyme
that could degrade insulin, and the proteasome [68].
Ubiquitin and ubiquitin-like proteins and type 1 diabetes
As described earlier within the section Protein pathway
involvement in disease, type 1 diabetes arises from an
immunological destruction of the insulin producing β-
cells. Although an environmental trigger is suspected in
this disease, a genetic predisposition to type 1 diabetes is
well established, with the HLA haplotype the major deter-
minant of risk, although other genes are also involved. It
has also been shown that the M55V substitution in the
SUMO4 gene is associated with the risk of developing type
1 diabetes [69] (reviewed in [70]). SUMO4 can be conju-
gated to the IKBA (IκBα) inhibitor of NFκB, leading to the
inhibition of NFκB activation. Expression of the M55V
variant of SUMO4 in human liver carcinoma HepG2 cells
results in a 5.5-fold increase in NFκB transcriptional activ-
ity compared with expression of the wild-type form of this
protein [69]. This increased activity can lead to increased
cytokine secretion, which could play a role in the immune
destruction of the β-cells.
Disease models, knockouts and assays
Commonly used animal models of type 2 diabetes
include the ob/ob and db/db mice, which are deficient in
leptin or the leptin receptor, respectively [71]. Common
rat models include the lean (wild-type) and obese (heter-
ozygous) fatty Zucker rats, which possess a leptin receptor
mutation and are normoglycemic [72]. Homozygous
mutant rats are obese and become diabetic. Although
common forms of human obesity are not due to such
defects in leptin or its receptor, obese subjects have gener-
ally been found to be leptin-resistant. High fat feeding will
readily induce obesity and diabetes in C57bl/6 mice and
these mice are frequently used as animal models of over-
feeding [73]. The laboratories of C.R. Kahn and M. White
at Harvard Medical School have been prominent in gener-
ating tissue-specific knockouts of the insulin receptor and
insulin receptor substrates, respectively. CBLB (Cbl-b)-
deficient mice were created by the D. Bowtell laboratory at
the Peter MacCallum Cancer Institute. A larger listing of
animal models of diabetes has been recently published
[74].
Disease targets and ligands
As of February 2008, evidence for the involvement of the
UPS in the pathogenesis of diabetes remained limited.
The downregulation of key signaling molecules such as
IRS1, IRS2 and AKT1 (Akt) in insulin resistant states and
the potential roles of the SOCS1 and SOCS3 proteins in
targeting these signaling molecules to ubiquitin-depend-
ent degradation is clearly intriguing. Similarly, the high
glucose stimulated degradation of IRS2, which plays an
important role in the survival of the insulin secreting β-
cells, is also interesting. Pharmacological inhibition of the
ligases responsible for this degradation would be of inter-
est. The increased insulin sensitivity in CBLB (Cbl-b)
knockout mice suggests that this ligase could also be a
potential target in spite of the lack of evidence that CBLB
ubiquitylates and downregulates the insulin receptor.
New frontiers in drug discovery
As of February 2008 there were only a limited number of
studies implicating the UPS in the pathogenesis of diabe-
tes and obesity. The most striking observations of these
investigations are that the UPS has a role in downregulat-
ing IRS proteins and thereby contributing to the two main
defects in diabetes, insulin resistance and impaired insu-
lin secretion. Reversing these effects could be a novel
approach in the treatment of diabetes and might be tested
using gene inactivation models of the SOCS1 and SOCS3
proteins. Such establishment of a clear role for these pro-
teins could identify them as targets for drug therapy in the
treatment of diabetes. In view of the pervasiveness of the
involvement of the UPS in cell signaling and receptor
internalization and trafficking, it is likely that many more
roles for the UPS in these disorders will be uncovered,
leading to novel drug targets. For example, drug inhibi-
tion of CBLB (Cbl-b) or of proteins that are involved in
downregulation of the insulin receptor via the endosomal
lysosomal system would be an interesting approach to
explore. The recent developments of large scale screening
technologies will hasten the pace of such discoveries. For
example, shRNA libraries against UPS genes have been
constructed [75] and could be used to screen for altera-
tions in insulin action in cultured cells.BMC Biochemistry 2008, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2091/9/S1/S6
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Note added in proof
Recently, Xu et al. described a CUL7 ubiquitin ligase com-
plex that also binds and targets IRS1 for ubiquitylation
and degredation [76].
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